HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: In the case of HDAC inhibitors, although they have demonstrated efficacy in hematologic malignancies such as cutaneous T-cell lymphoma but their use in solid tumors has often been limited by toxicity and context-specific resistance mechanisms (99).